Neurogene Inc. Files 8-K: Regulation FD & Exhibits

Ticker: NGNE · Form: 8-K · Filed: Nov 6, 2025 · CIK: 1404644

Sentiment: neutral

Topics: disclosure, filing, sec

Related Tickers: NGNE

TL;DR

NGNE filed an 8-K for Nov 6, 2025, covering Reg FD and exhibits. Standard reporting.

AI Summary

Neurogene Inc. filed an 8-K on November 6, 2025, reporting on Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Neoleukin Therapeutics, Inc., is located at 535 W 24th Street, New York, NY. This filing does not contain specific financial figures or event details beyond the reporting of these categories.

Why It Matters

This 8-K filing indicates that Neurogene Inc. is making required disclosures to the SEC, which is standard for publicly traded companies. It signals ongoing compliance and reporting activities.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for disclosures and exhibits, not indicating any specific negative events or financial distress.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Neurogene Inc.?

The primary purpose of this 8-K filing is to report on Regulation FD Disclosure and Financial Statements and Exhibits, as of November 6, 2025.

What was Neurogene Inc.'s former company name?

Neurogene Inc.'s former company name was Neoleukin Therapeutics, Inc.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on November 6, 2025.

What is Neurogene Inc.'s principal executive office address?

Neurogene Inc.'s principal executive office is located at 535 W 24th Street, 5th Floor, New York, NY 10011.

Under which section of the Securities Exchange Act is this 8-K filed?

This 8-K is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.

Filing Stats: 593 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2025-11-06 07:31:11

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On November 6, 2025, Neurogene Inc. (the "Company") issued a press release announcing the dosing of the first patient in the Embolden TM registrational trial of NGN-401 for the treatment of Rett syndrome. A copy of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K. On November 6, 2025, the Company also made available on its website an updated corporate presentation including the information regarding the ongoing enrollment and dosing in the Embolden trial. A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K. The information in this Item 7.01 and Exhibits 99.1 and 99.2 attached hereto are being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information or Exhibits 99.1 and 99.2 be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference to such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated November 6, 2025 99.2 Corporate Presentation (November 6, 2025) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. NEUROGENE INC. Date: November 6, 2025 By: /s/ Christine Mikail Name: Christine Mikail Title: President, Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing